Literature DB >> 16575108

Drug resistance in amoebiasis.

Devendra Bansal1, Nancy Malla, R C Mahajan.   

Abstract

Amoebiasis caused by Entamoeba histolytica, is a major public health problem in developing countries. Morphologically similar E. dispar is non pathogenic. Because of the redefinition of E. histolytica and E. dispar, and the limited number of antiamoebic drugs available, a new approach to treat such individuals is necessary. The cost of treating asymptomatic individuals is highly exorbitant and not justifiable. The indiscriminate use of antiamoebic drugs can result in increased minimum inhibitory concentration (MIC) values against Entamoeba species, and treatment failure may emerge as an important public health problem. Development of new antiamoebic drugs is still in infancy and vaccine development appears to be distant dream. In future, the development of drug resistance may seriously affect the control of disease. This review discusses the factors involved in drug resistance mechanisms developed by the parasite.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16575108

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  17 in total

Review 1.  The future for vaccine development against Entamoeba histolytica.

Authors:  Jeanie Quach; Joëlle St-Pierre; Kris Chadee
Journal:  Hum Vaccin Immunother       Date:  2014-02-06       Impact factor: 3.452

2.  The Potential of Lactobacillus casei and Entercoccus faecium Combination as a Preventive Probiotic Against Entamoeba.

Authors:  Nitya Sarjapuram; Niharika Mekala; Meetali Singh; Utpal Tatu
Journal:  Probiotics Antimicrob Proteins       Date:  2017-06       Impact factor: 4.609

3.  Structure of an ADP-ribosylation factor, ARF1, from Entamoeba histolytica bound to Mg(2+)-GDP.

Authors:  Dmitry A Serbzhinskiy; Matthew C Clifton; Banumathi Sankaran; Bart L Staker; Thomas E Edwards; Peter J Myler
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-04-21       Impact factor: 1.056

4.  Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica.

Authors:  Fabrice F Boyom; Patrick V T Fokou; Lauve R Y Tchokouaha; Thomas Spangenberg; Alvine N Mfopa; Ruffin M T Kouipou; Cedric J Mbouna; Valerie F Donkeng Donfack; Paul H A Zollo
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

Review 5.  Vaccines to combat the neglected tropical diseases.

Authors:  Jeffrey M Bethony; Rhea N Cole; Xiaoti Guo; Shaden Kamhawi; Marshall W Lightowlers; Alex Loukas; William Petri; Steven Reed; Jesus G Valenzuela; Peter J Hotez
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

6.  Drug repositioning: antiprotozoal activity of terfenadine against Entamoeba histolytica trophozoites.

Authors:  Itzia Azucena Rangel-Castañeda; Araceli Castillo-Romero; Gloria León-Ávila; Martin Zermeño-Ruiz; José Manuel Hernández-Hernández
Journal:  Parasitol Res       Date:  2021-11-06       Impact factor: 2.289

7.  Effects of a putrescine analog on Giardia lamblia.

Authors:  C Maia; A Lanfredi-Rangel; K G Santana-Anjos; M F Oliveira; W De Souza; M A Vannier-Santos
Journal:  Parasitol Res       Date:  2008-04-24       Impact factor: 2.289

8.  Use of bacterially expressed dsRNA to downregulate Entamoeba histolytica gene expression.

Authors:  Carlos F Solis; Julien Santi-Rocca; Doranda Perdomo; Christian Weber; Nancy Guillén
Journal:  PLoS One       Date:  2009-12-23       Impact factor: 3.240

9.  Furanocoumarins from Ruta chalepensis with Amebicide Activity.

Authors:  Aldo Fabio Bazaldúa-Rodríguez; Ramiro Quintanilla-Licea; María Julia Verde-Star; Magda Elizabeth Hernández-García; Javier Vargas-Villarreal; Jesús Norberto Garza-González
Journal:  Molecules       Date:  2021-06-16       Impact factor: 4.411

Review 10.  G protein signaling in the parasite Entamoeba histolytica.

Authors:  Dustin E Bosch; David P Siderovski
Journal:  Exp Mol Med       Date:  2013-03-22       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.